Basic Info
  • Grade: Pharmaceutical Grade

    Factory Location: QUANZHOU

    Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

  • Sample Provided: no

    Bictegravir is a novel integrase inhibitor developed by Gilead Sciences scientists. In vitro and clinical results were produced by Gilead in the summer of 2016. As of June 2016, Bictegravir was used as a single tablet regimen in combination with tenofovir alafinamide (TAF) and emtricitabine (FTC) for the treatment of hiv-1 infection.

    Indication: HIV-1 infection

    All the products under the patent are only for R&D use.

    Patent from Gilead Sciences, expiry date(The U.S):Dec.19,2033

     

Send your message to this supplier
  • From:
  • To:
    Quanzhou Fortune Biopharma Co.,Ltd.
  • Send a Copy to this Email
  • Message:
    Upload Images / Files
    - Supports jpg, jpeg, png,
     gif, pdf, doc, docx,
     xls, xlsx, txt, rar and zip
    - Max upload 3 files;
     Max  total size: 3MB
    (0/3)

    Enter between 20 to 4,000 characters.This is not what you are looking for ? Post a Sourcing Request Now

  • Verification:
PharmaSources Customer Service